A 3-year international study revealed that long-term treatment with upadacitinib led to sustained remission in many patients with moderate to severe ulcerative colitis, even after previous response to short-term treatment with the same drug. The study demonstrated high remission rates, including for patients with prior biologic treatment failure, and provided insights into the drug's long-term safety and efficacy.

Source: The Lancet Gastroenterology & Hepatology